反转录病毒介导基因转移治疗脑肿瘤的安全性研究

Safety assessments of retrovirus-mediated gene therapy for glioma

目的检测反转录病毒介导的HSV-tk／ACV系统的安全性。方法DNA聚合酶链式反应（PCR）、反转录PCR（RT／PCR），Southern杂交及neo基因和LacZ基因补救分析：细胞接种、X-gal染色、TK基因PCR和病理切片检查等。结果从DNA、RNA水平和病毒活体水平对产HSV-tk病毒包装细胞（TK／VPC）、C5转TK基因细胞和实验动物血流中未能检测到具有复制能力的野生型反转录病毒（RCR）；PA317／BAG，PA／317／TK产病毒细胞（VPC）于动物体内存活期不超过一个月，未形成肿瘤，无严重炎症反应，HSV-tk／ACV系统及代谢产物无明显毒副作用。结论反转录病毒介导的HSV-tk／ACV系统在动物体内取得了安全的结果。

Objective To assess the safety of HSV-tk/ACV system mediated by replication-competent retrovirus (RCR) on gene therapy for glioma. Methods The methods used included polymerasechain reaction (PCR), reverse transcripted PCR (RT/PCR), Southern blot, rescue assay of Neo andlacZ gene, cell implantation, PCR for HSV-tk, X-gal staining and histomicrosection. Results RCRwere not detected in HSV-tk virus producing cell line (TK/VPC), C6TK genetically modified cell andblood samples from the tested animals on DNA, RNA and virus level respective1y. The survival time ofvirus-producting cells (VPC) of PA317/BAG and PA/317/TK in the animals'body was not more thanone month. No inflammatory response and tumor occurred. No obvious side effects or pathologicalchanges were attributed to the HSV-tk/ACV system and metabolites. Conclusions The HSV-tk/ACVsystem mediated by retrovirus was safe for the treatment of brain tumors.